Tarsus Pharmaceuticals CEO and board chair Bobak Azamian sold 10,000 shares across two transactions at $90.27 to $91.27 per share. The transactions leave Azamian with 827,991 shares, giving investors the reported post-sale ownership position of the company’s president, CEO and board chair.

Key Highlights

  • The transactions occurred on 4 September 2026.
  • Both transactions used SEC transaction code S, indicating open-market sales.
  • Bobak Azamian owned 827,991 shares after the transactions.

The sale was completed through two transactions. The transactions took place on 4 September 2026. Both entries carried SEC transaction code S, which identifies an open-market sale. Code S distinguishes the entries as sales rather than awards, purchases, tax-related withholding, option exercises or gifts.

Post-Transaction Ownership

Azamian owned 827,991 shares after the transactions. The reported balance represents his ownership position following the two sales. The ownership figure gives investors the stated post-transaction share balance for Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS)’s senior executive and board leader.